The Safety and Efficacy of Calcitonin Gene-Related Peptide (CGRP) Monoclonal Antibodies for the Preventive Treatment of Migraine: A Protocol for Multiple-Treatment Systematic Review and Meta-Analysis

Jaime Fernández-Bravo-Rodrigo, Carlos Pascual-Morena, Amparo Flor-García, Alicia Saz-Lara, Irene Sequí-Dominguez, Celia Álvarez-Bueno, Dolores Barreda-Hernández and Iván Cavero-Redondo
Additional contact information
Jaime Fernández-Bravo-Rodrigo: Health and Social Research Center, Universidad de Castilla—La Mancha, 16071 Cuenca, Spain
Carlos Pascual-Morena: Health and Social Research Center, Universidad de Castilla—La Mancha, 16071 Cuenca, Spain
Amparo Flor-García: Pharmacy Service, Hospital Virgen de la Luz, 16002 Cuenca, Spain
Alicia Saz-Lara: Health and Social Research Center, Universidad de Castilla—La Mancha, 16071 Cuenca, Spain
Irene Sequí-Dominguez: Health and Social Research Center, Universidad de Castilla—La Mancha, 16071 Cuenca, Spain
Celia Álvarez-Bueno: Health and Social Research Center, Universidad de Castilla—La Mancha, 16071 Cuenca, Spain
Dolores Barreda-Hernández: Pharmacy Service, Hospital Virgen de la Luz, 16002 Cuenca, Spain
Iván Cavero-Redondo: Health and Social Research Center, Universidad de Castilla—La Mancha, 16071 Cuenca, Spain

IJERPH, 2022, vol. 19, issue 3, 1-9

Abstract: Background: Migraine is a common and disabling primary headache disorder, associated with many medical comorbidities, highly prevalent, with complex treatment and management. Currently, monoclonal antibodies targeting the trigeminal sensory neuropeptide, calcitonin gene-related peptide (CGRP), are available. The aim of this protocol is to provide a review comparing the effects and safety profile of different monoclonal antibodies in migraine patients. Methods: The literature search will be performed through the MEDLINE, Embase, CENTRAL, ClinicalTrials.gov, the WHO International Clinical Trials Registry Platform (ICTRP), Web of Science and Scopus databases, following the PICO strategy. Real World studies and randomized clinical trials assessing the effect of monoclonal antibodies against CGRP interventions (erenumab, eptinezumab, fremanezumab and galcanezumab) on monthly migraine days (MMD), monthly headache days (MHD), headache impact test (HIT-6) and triptan days of use (TriD) will be included. In Real World studies, the DerSimonian and Laird method will be used to calculate pooled estimates of the mean change difference and in randomized clinical trials, a network meta-analysis will be performed to estimate the comparative effects of different monoclonal antibodies against CGRP. Results: The findings of this study will be reported in a peer-reviewed journal. Conclusions: This study will provide evidence to health professionals on the efficacy and safety of different monoclonal antibodies against CGRP on the outcomes studied.

Keywords: monoclonal antibodies; calcitonin gene-related peptide (CGRP); migraine prevention; erenumab; eptinezumab; fremanezumab; galcanezumab; protocol; review; meta-analysis (search for similar items in EconPapers)
JEL-codes: I I1 I3 Q Q5 (search for similar items in EconPapers)
Date: 2022
References: View complete reference list from CitEc
Citations:

Downloads: (external link)
https://www.mdpi.com/1660-4601/19/3/1753/pdf (application/pdf)
https://www.mdpi.com/1660-4601/19/3/1753/ (text/html)

Related works:
This item may be available elsewhere in EconPapers: Search for items with the same title.

Export reference: BibTeX RIS (EndNote, ProCite, RefMan) HTML/Text

Persistent link: https://EconPapers.repec.org/RePEc:gam:jijerp:v:19:y:2022:i:3:p:1753-:d:741718

Access Statistics for this article

IJERPH is currently edited by Ms. Jenna Liu

More articles in IJERPH from MDPI
Bibliographic data for series maintained by MDPI Indexing Manager ().